Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$15.06
+4.6%
$13.88
$10.83
$63.00
$294.42M1.5144,833 shs44,912 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.19
+1.7%
$1.04
$0.28
$2.18
$432.45M1.178.55 million shs1.40 million shs
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$3.53
$1.12
$11.30
$96.26M2.274.33 million shs1.20 million shs
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$34.20
+4.4%
$26.99
$18.35
$35.00
$413.48M144,718 shs111,643 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+4.35%+3.37%+10.43%-98.12%-98.12%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+3.54%-0.85%-2.50%+77.30%-38.74%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
+0.89%+3.67%+28.68%+31.79%+12.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.8535 of 5 stars
4.70.00.03.72.51.70.6
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.1449 of 5 stars
3.33.00.00.00.02.50.6
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
4.254 of 5 stars
3.34.00.03.03.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.40
Buy$25.5069.32% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.50
Moderate Buy$3.23171.01% Upside
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
0.00
N/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
2.67
Moderate Buy$69.50103.22% Upside

Current Analyst Ratings Breakdown

Latest SNSS, LXRX, XOMA, and CBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/11/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
8/7/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.20 ➝ $1.90
7/14/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$27.00
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/24/2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
5/28/2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K29,442.30N/AN/A$6.92 per share2.18
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$31.08M13.91N/AN/A$0.36 per share3.31
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$2.07M0.00N/AN/A$1.42 per share0.00
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
$28.49M14.51N/AN/A$5.99 per share5.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$34.93N/AN/AN/AN/A-106.06%-86.60%N/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%N/A
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
-$23.33M-$2.70N/AN/AN/AN/A-179.05%-72.27%N/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)

Latest SNSS, LXRX, XOMA, and CBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million
8/6/2025Q2 2025
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/A
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
9.21
9.21
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.43
4.16
4.16
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/A
7.74
7.74
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1.41
4.88
4.88

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
28.41%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
95.92%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
4.00%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
13.90%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
4.22%
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million18.77 millionNo Data
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140363.40 million312.89 millionOptionable
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
2418.09 millionN/AOptionable
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
1012.09 million10.99 millionOptionable

Recent News About These Companies

Q3 EPS Estimates for XOMA Royalty Reduced by Leerink Partnrs
Leerink Partnrs Expects Reduced Earnings for XOMA Royalty
XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$15.06 +0.66 (+4.58%)
As of 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.19 +0.02 (+1.71%)
Closing price 04:00 PM Eastern
Extended Trading
$1.18 -0.01 (-0.84%)
As of 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Sunesis Pharmaceuticals stock logo

Sunesis Pharmaceuticals NASDAQ:SNSS

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

XOMA Royalty stock logo

XOMA Royalty NASDAQ:XOMA

$34.20 +1.45 (+4.43%)
Closing price 04:00 PM Eastern
Extended Trading
$34.30 +0.10 (+0.31%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.